Annual CFO
-$4.99 M
+$1.61 M+24.42%
31 December 2023
Summary:
Evoke Pharma annual cash flow from operations is currently -$4.99 million, with the most recent change of +$1.61 million (+24.42%) on 31 December 2023. During the last 3 years, it has risen by +$1.65 million (+24.81%). EVOK annual CFO is now -184.87% below its all-time high of -$1.75 million, reached on 31 December 2012.EVOK Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$818.70 K
+$1900.00+0.23%
30 September 2024
Summary:
Evoke Pharma quarterly cash flow from operations is currently -$818.70 thousand, with the most recent change of +$1900.00 (+0.23%) on 30 September 2024. Over the past year, it has increased by +$222.90 thousand (+21.40%). EVOK quarterly CFO is now -198.03% below its all-time high of -$274.70 thousand, reached on 30 September 2013.EVOK Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$5.32 M
+$222.90 K+4.02%
30 September 2024
Summary:
Evoke Pharma TTM cash flow from operations is currently -$5.32 million, with the most recent change of +$222.90 thousand (+4.02%) on 30 September 2024. Over the past year, it has increased by +$1.06 million (+16.61%). EVOK TTM CFO is now -1089.63% below its all-time high of -$447.60 thousand, reached on 31 March 2012.EVOK TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EVOK Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +24.4% | +21.4% | +16.6% |
| 3 y3 years | +24.8% | +86.1% | +55.9% |
| 5 y5 years | +28.6% | +22.7% | +9.2% |
EVOK Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +59.6% | at high | +86.1% | -6.8% | +56.9% |
| 5 y | 5 years | at high | +59.6% | at high | +86.1% | -6.8% | +56.9% |
| alltime | all time | -184.9% | +59.6% | -198.0% | +86.1% | -1089.6% | +57.4% |
Evoke Pharma Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$818.70 K(-0.2%) | -$5.32 M(-4.0%) |
| June 2024 | - | -$820.60 K(-68.2%) | -$5.55 M(-6.5%) |
| Mar 2024 | - | -$2.58 M(+133.2%) | -$5.93 M(+19.0%) |
| Dec 2023 | -$4.99 M(-24.4%) | -$1.11 M(+6.2%) | -$4.99 M(-21.9%) |
| Sept 2023 | - | -$1.04 M(-13.7%) | -$6.39 M(-0.9%) |
| June 2023 | - | -$1.21 M(-26.0%) | -$6.44 M(-2.5%) |
| Mar 2023 | - | -$1.63 M(-34.9%) | -$6.61 M(+0.2%) |
| Dec 2022 | -$6.60 M(-46.6%) | -$2.51 M(+127.7%) | -$6.60 M(+8.4%) |
| Sept 2022 | - | -$1.10 M(-19.9%) | -$6.09 M(-44.0%) |
| June 2022 | - | -$1.37 M(-14.9%) | -$10.88 M(-1.2%) |
| Mar 2022 | - | -$1.61 M(-19.1%) | -$11.01 M(-10.8%) |
| Dec 2021 | -$12.35 M(+86.3%) | -$2.00 M(-66.1%) | -$12.35 M(+2.4%) |
| Sept 2021 | - | -$5.89 M(+290.1%) | -$12.07 M(+51.1%) |
| June 2021 | - | -$1.51 M(-48.9%) | -$7.99 M(-0.6%) |
| Mar 2021 | - | -$2.95 M(+72.5%) | -$8.03 M(+21.1%) |
| Dec 2020 | -$6.63 M(+15.1%) | -$1.71 M(-5.5%) | -$6.63 M(+9.3%) |
| Sept 2020 | - | -$1.81 M(+16.3%) | -$6.07 M(+14.1%) |
| June 2020 | - | -$1.56 M(+0.3%) | -$5.31 M(-1.3%) |
| Mar 2020 | - | -$1.55 M(+35.2%) | -$5.39 M(-6.5%) |
| Dec 2019 | -$5.76 M(-17.4%) | -$1.15 M(+8.4%) | -$5.76 M(-1.7%) |
| Sept 2019 | - | -$1.06 M(-35.0%) | -$5.86 M(-1.5%) |
| June 2019 | - | -$1.63 M(-15.5%) | -$5.95 M(-2.2%) |
| Mar 2019 | - | -$1.93 M(+54.3%) | -$6.09 M(-12.8%) |
| Dec 2018 | -$6.98 M | -$1.25 M(+8.6%) | -$6.98 M(-17.5%) |
| Sept 2018 | - | -$1.15 M(-34.7%) | -$8.46 M(-11.0%) |
| June 2018 | - | -$1.76 M(-37.5%) | -$9.51 M(-3.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | -$2.82 M(+3.1%) | -$9.85 M(+13.0%) |
| Dec 2017 | -$8.72 M(+0.1%) | -$2.73 M(+24.2%) | -$8.72 M(+18.6%) |
| Sept 2017 | - | -$2.20 M(+5.0%) | -$7.35 M(-2.9%) |
| June 2017 | - | -$2.10 M(+24.3%) | -$7.57 M(-1.7%) |
| Mar 2017 | - | -$1.69 M(+23.2%) | -$7.70 M(-11.5%) |
| Dec 2016 | -$8.71 M(-17.0%) | -$1.37 M(-43.4%) | -$8.71 M(-11.1%) |
| Sept 2016 | - | -$2.42 M(+8.4%) | -$9.79 M(-0.9%) |
| June 2016 | - | -$2.23 M(-17.1%) | -$9.88 M(-3.1%) |
| Mar 2016 | - | -$2.69 M(+9.7%) | -$10.19 M(-2.9%) |
| Dec 2015 | -$10.50 M(-8.7%) | -$2.45 M(-2.1%) | -$10.50 M(-0.6%) |
| Sept 2015 | - | -$2.50 M(-1.6%) | -$10.56 M(-11.8%) |
| June 2015 | - | -$2.54 M(-15.1%) | -$11.97 M(-4.2%) |
| Mar 2015 | - | -$3.00 M(+18.8%) | -$12.50 M(+8.6%) |
| Dec 2014 | -$11.50 M(+278.3%) | -$2.52 M(-35.6%) | -$11.50 M(+5.8%) |
| Sept 2014 | - | -$3.91 M(+27.5%) | -$10.87 M(+50.3%) |
| June 2014 | - | -$3.07 M(+53.3%) | -$7.23 M(+57.4%) |
| Mar 2014 | - | -$2.00 M(+5.9%) | -$4.59 M(+51.1%) |
| Dec 2013 | -$3.04 M(+73.7%) | -$1.89 M(+587.8%) | -$3.04 M(+68.5%) |
| Sept 2013 | - | -$274.70 K(-36.1%) | -$1.80 M(-1.5%) |
| June 2013 | - | -$429.80 K(-3.7%) | -$1.83 M(+4.7%) |
| Mar 2013 | - | -$446.50 K(-31.6%) | -$1.75 M(-0.1%) |
| Dec 2012 | -$1.75 M(-39.5%) | -$652.80 K(+116.5%) | -$1.75 M(+59.5%) |
| Sept 2012 | - | -$301.50 K(-13.4%) | -$1.10 M(+37.9%) |
| June 2012 | - | -$348.00 K(-22.3%) | -$795.60 K(+77.7%) |
| Mar 2012 | - | -$447.60 K | -$447.60 K |
| Dec 2011 | -$2.89 M | - | - |
FAQ
- What is Evoke Pharma annual cash flow from operations?
- What is the all time high annual CFO for Evoke Pharma?
- What is Evoke Pharma annual CFO year-on-year change?
- What is Evoke Pharma quarterly cash flow from operations?
- What is the all time high quarterly CFO for Evoke Pharma?
- What is Evoke Pharma quarterly CFO year-on-year change?
- What is Evoke Pharma TTM cash flow from operations?
- What is the all time high TTM CFO for Evoke Pharma?
- What is Evoke Pharma TTM CFO year-on-year change?
What is Evoke Pharma annual cash flow from operations?
The current annual CFO of EVOK is -$4.99 M
What is the all time high annual CFO for Evoke Pharma?
Evoke Pharma all-time high annual cash flow from operations is -$1.75 M
What is Evoke Pharma annual CFO year-on-year change?
Over the past year, EVOK annual cash flow from operations has changed by +$1.61 M (+24.42%)
What is Evoke Pharma quarterly cash flow from operations?
The current quarterly CFO of EVOK is -$818.70 K
What is the all time high quarterly CFO for Evoke Pharma?
Evoke Pharma all-time high quarterly cash flow from operations is -$274.70 K
What is Evoke Pharma quarterly CFO year-on-year change?
Over the past year, EVOK quarterly cash flow from operations has changed by +$222.90 K (+21.40%)
What is Evoke Pharma TTM cash flow from operations?
The current TTM CFO of EVOK is -$5.32 M
What is the all time high TTM CFO for Evoke Pharma?
Evoke Pharma all-time high TTM cash flow from operations is -$447.60 K
What is Evoke Pharma TTM CFO year-on-year change?
Over the past year, EVOK TTM cash flow from operations has changed by +$1.06 M (+16.61%)